HOME >> BIOLOGY >> NEWS
Infection-fighting strategy backfires in cystic fibrosis

Cells sent to fight infections in the lungs of cystic fibrosis patients actually enhance the development of permanent bacterial infections, according to researchers at National Jewish Medical and Research Center. Infections with the bacteria Pseudomonas are a major cause of sickness and death in cystic fibrosis patients. The findings, published in the June issue of Infection and Immunity, suggest new treatment strategies for patients with cystic fibrosis.

"Pseudomonas can use the remnants of dead white blood cells to develop a protective biofilm, which helps the bacteria establish a permanent infection," said National Jewish pulmonologist Jerry Nick, M.D., senior author on the paper. "So, ironically, the very cells sent to fight infection may contribute to our inability to eradicate the Pseudomonas infection in cystic fibrosis patients."

Cystic fibrosis (CF) is a genetic disorder affecting about 30,000 people in the United States, and is the most common genetic disorder among Caucasian people. People with CF produce abnormal mucus that obstructs the airways and leads to chronic lung infections. The disease is fatal, but life expectancy for patients has increased dramatically in recent years, from 14 years in the mid-1980s to 35 years today. National Jewish has one of the largest adult cystic fibrosis clinics in the nation.

Pseudomonas aeruginosa is widespread in the environment and repeatedly infects most CF patients. Aggressive treatment with antibiotics successfully fights most initial infections. Over time, however, P. aeruginosa infections often become permanent; more than 80% of adults with CF are chronically infected with P. aeruginosa. The chronic infection and inflammation associated with P. aeruginosa accelerate damage to the lungs, leading ultimately to respiratory failure and death.

Researchers believe that Pseudomonas establishes a chronic infection in the airway of CF patients by creating a biofilm, a three-dimensional structure c
'"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
2-Jun-2005


Page: 1 2 3

Related biology news :

1. New strategy for treating allergic disorders
2. Does EPA have an adequate strategy to oversee nanotechnologies?
3. High blood pressure medication strategy proves effective in Hispanic women
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Scientists identify new strategy for preventing acute and chronic brain disease
6. International risk research strategy and funding needed for nanotech safety
7. Study shows metabolic strategy of stressed cell
8. Trojan horse strategy defeats drug-resistant bacteria
9. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
10. Drug strategy makes cancer genes get lost in translation
11. Researchers develop new strategy for the treatment of CML

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Infection fighting strategy backfires cystic fibrosis

(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... 18, 2013) The AGA Research Foundation announced a ... relationship between the gut microbiota, one of today,s most ... , The AGA Research Awards Panel selected Andrew ... General Hospital and Harvard Medical School, Boston, as the ... Chan will receive $25,000 of funding, commencing in July ...
(Date:5/17/2013)... the science and technology of the region and ... inaugural Atlanta Science Festival, March 22-29, 2014. With ... K-12 schools and universities, the festival will host ... adults at venues across the city. Learn more ... Atlanta Science Festival is a collaboration of scientific, ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2
(Date:5/21/2013)... 21, 2013 Savoury Systems International (SSI), ... Dale Braddy to Southeastern USA Sales Broker. Braddy’s new ... muscle in the Southeast. , In 2004 ... and supplier to food processors and industrial manufacturers. ... the food industry and has over 25 years of ...
(Date:5/21/2013)... Clinverse, Inc. , a global ... announced today it has formed a strategic alliance ... FLS eClinical commerce platform aggregates data collected through ... ™, Aggregate Spend Solutions’ recently-launched flagship product, is ... transfer of value at investigator meetings or any ...
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 Smarter ... outdoor security solutions, today announced that Genzyme, a Sanofi ... units of Door Detective® CL for a multi-use facility ... installed in four other Genzyme buildings, this latest order ... with the tailgate detection device improving doorway ...
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5
Cached News: